Ionis Partner GSK Wins FDA Approval for Hibsago to Treat Chronic Hepatitis B

• FDA approved GSK’s Hibsago (bepirovirsen), licensed from Ionis Pharmaceuticals, for chronic hepatitis B in eligible adults alongside nucleos(t)ide analogue therapy.
• Ionis is eligible for additional regulatory and sales milestone payments, plus tiered royalties of 10-12% on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020102530) on October 21, 2026, and is solely responsible for the information contained therein.